Video Experimental Relacionado
Updated: Jan 8, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Liquidación drástica de psoriasis extensa en un paciente pediátrico tratado con upadacitinib: reporte de un caso
Jenna Mistry1, Michal Moshkovich1, Maxwell Sauder2,3
1Temerty Faculty of Medicine, University of Toronto, ON, Canada.
Abstract:
We present a unique case of an 8-year-old boy with severe, treatment-refractory palmoplantar psoriasis and genital involvement, unresponsive to nine systemic agents, including multiple biologics and TYK2 inhibition with deucravacitinib. Following years of debilitating symptoms and functional impairment, he achieved near-complete resolution within 2 weeks of initiating upadacitinib monotherapy. This dramatic and sustained response highlights the potential role of JAK1 inhibition in modulating complex inflammatory pathways in pediatric psoriasis, particularly in challenging anatomic sites and refractory cases.
Videos de Conceptos Relacionados
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pharmacokinetics in Pediatric Patients: Drug Metabolism
